The Single Best Strategy To Use For active pharmaceutical ingredient manufacturers
“The present problem has uncovered some structural weaknesses within the EU’s medicines offer chain as well as a substantial dependence on non-EU international locations for active pharmaceutical ingredients,” Kyriakides reported. She suggested that offer chain issues be addressed in an EU pharmaceutical system predicted for being introduced